SWK — Investor Presentation (November 2021)
35 slides from SWK's investor presentation, Nov 23, 2021

Slide 1: Collaborative Approach to Life Science Financing
SWK Holdings Collaborative Approach to Life Science Financing Shareholder Presentation November 17, 2021

Slide 2: Forward-looking and Cautionary Statements
Forward-looking and Cautionary Statements Statements in this presentation that are not strictly historical, and any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements within the meaning of the federal securities

Slide 3: SWK Holdings - Overview
SWK Holdings - Overview 3 Underserved, High-Need Market Demonstrated Success, Attractive Returns Focus on Shareholder Returns Custom financing solutions for commercial-stage healthcare companies and royalty owners • SWK targets $5mm to $25mm financings, a market niche that is largely ignored by larg

Slide 4: SWK Holdings - Segments
SWK Holdings - Segments LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • Senior secured term loans • Royalties • Synthetic royalties • Product acquisitions • Peptelligence® and ProPerma™ dosing technologies • CDMO services • 505b2 drug development SWK operates through two segments: Life Science Sp

Slide 5: Life Science Finance Opportunity
Life Science Finance Opportunity Achieve high current yield from investment in non-correlated assets Access to capital is challenging for small/mid-sized life science companies - Few participants exist for sub-$25mm life science financings Life science products are highly portable - Approved & marke

Slide 6: Value Creation Strategy
Value Creation Strategy Deploy balance sheet capital into secured financing portfolio • SWK has established reputation as a go-to capital provider for this underserved market • Majority of financings structured with warrants or other equity-like upside features to enhance return profile Selectively

Slide 7: Book Value Components
Book Value Components Tangible Finance Book Value / Share = $17.50 • Excludes value of deferred tax asset, net Enteris intangibles and goodwill*, and Enteris PP&E • SWK’s targets 10%+ CAGR of tangible finance book value / share Plus: Enteris Biopharma Net Book Value / Share = $1.10 • In August 2019,

Slide 8: Corporate Milestones
Corporate Milestones 2014 „Ï $113mm raised through private placement and rights offering „Ï Ended year with $93mm yielding assets 2015 „Ï Winston Black named CEO „Ï 1/10 effective reverse stock split „Ï Ended year with $99mm yielding assets 2016 „Ï Team rebuilt and investment process improved „Ï End

Slide 9: Third Quarter 2021 Recap
Third Quarter 2021 Recap CONFIDENTIAL 9 CORPORATE UPDATES FINANCE RECEIVABLES UPDATES • Conclusion of strategic review process with SWK to focus on specialty finance receivables business • SWK evaluating ongoing dividend and additional leverage • As of September 30, 2021, tangible book value per sha

Slide 10: Finance Segment Portfolio Overview: 3Q21
Finance Segment Portfolio Overview: 3Q21 * Finance receivables and marketable investments; does not include new or repaid finance receivables closed post-quarter ** Includes public company warrants; private warrants carried at zero value / not valued on balance sheet ***As of 11/16/21 • Yielding Ass

Slide 11: Financial Snapshot
Financial Snapshot * Defined as finance receivables plus marketable investments ** Eliminates provision for income taxes, Enteris intangibles amortization, and non-cash mark-to-market changes on warrant assets and equity securities; see reconciliation on page 29; 2019 Non-GAAP Adjusted Net Income wa

Slide 12: Financing Strategy: Effective Yield
Financing Strategy SWK Targets Low-to-Mid Teens Effective Yields 3Q21 Finance Segment Effective Yield was 13.8% * Finance receivables plus marketable investment; includes non-accruals ** Effective yield is the rate at which income is expected to be recognized pursuant to the Company’s revenue recogn

Slide 13: Financing Strategy: Realized Yield vs Effective Yield
Financing Strategy SWK’s Portfolio Realized Yield Has Consistently Exceeded the Projected Yield as Actual Receipts Exceeded Internal Forecasts *Portfolio Realized Yield is inclusive of all fees and is calculated based on the simple average of finance receivables at the beginning and end of period Re

Slide 14: Current Structured Credit Portfolio
Current Structured Credit Portfolio

Slide 15: Current Royalty Portfolio
Current Royalty Portfolio S$54miion oye poner ft al Kibet ZeaLviso Sa seaeatan-sony || tetnttn-toary |] sanan-Ronty ¢PDL BioPharma Se ba

Slide 16: Portfolio Realizations
Portfolio Realizations „H As of November 16, 2021, SWK has exited 22 financings for a total 1.4x CoC return and 21% weighted average IRR .. 19 resulted in positive realizations with a cumulative 1.5x CoC and weighted average 29% IRR .. SynCardia position was sold to distressed private equity firm wi

Slide 17: Portfolio Realizations to Strategic Buyers
Portfolio Realizations to Strategic Buyers „H 13 realizations to strategic buyers demonstrated a median 28% LTV of SWK¡¦s original loan value „H 10 of the 13 businesses were not profitable at time of sale, validating SWK¡¦s revenue and IP-based underwriting methodology $ in mm Target Buyer Closing D

Slide 18: Sourcing
Sourcing „H SWK has a well-developed and diversified sourcing network „H SWK balances proprietary opportunities with deal flow from trusted, boutique investment banks and brokers „H SWK typically faces limited competition due to proprietary sourcing network and focus on sub-$20mm financings „H From

Slide 19: Financing Structures
Financing Structures 19 Product Acquisition • Primarily first lien senior secured loans, though will selectively evaluate second lien opportunities • Typically include covenants, prepayment penalties, origination and exit fees, and warrant coverage • Provide working capital to support product commer

Slide 20: Value Proposition to Partners
Value Proposition to Partners „H Smaller companies often don¡¦t have financial profile to qualify for traditional financing sources „H Companies in this niche often have few options outside of a dilutive equity raise „H The IPO market is largely closed to companies of this size requiring expensive a

Slide 21: Historical Financing: Narcan Royalty
Historical Financing: Narcan Royalty 21 OPPORTUNITY SOLUTION • Opiant is a publicly-traded drug development company that receives a royalty on Narcan for developing the drug’s unique formulation • Novel formulation has a faster time to onset and more convenient and safer administration • Opiant need

Slide 22: Historical Financing: Galil Medical
Historical Financing: Galil Medical 22 OPPORTUNITY SOLUTION • In 2014, Galil was on the cusp of accelerating revenue growth, but was not yet cashflow positive and could not tap traditional financing channels • Galil needed additional capital to run clinical trials and expand its sales force • In Dec

Slide 23: Enteris BioPharma Acquisition – A Transformational Opportunity
Enteris BioPharma Acquisition – A Transformational Opportunity 23 • Natural extension to SWK’s existing royalty monetization business, which generates income via royalties on life science products in a mix of structures • Enteris offers opportunity to create wholly-owned portfolio of milestones and

Slide 24: Enteris Corporate Overview
Enteris Corporate Overview Commercial Platform Proven Technology, Late-Stage Commercial Partnerships, and Internal Pipeline Drug Delivery Technology Internal 505(b)(2) Pipeline Company Highlights • Peptelligence and ProPerma allow for oral delivery of drugs that are typically injected, including pep

Slide 25: Enteris: Cara Therapeutics and Oral KORSUVA
Enteris: Cara Therapeutics and Oral KORSUVA™ 25 Oral KORSUVA Licensing Agreement Milestone Payment • Formulated with Enteris’ Peptelligence technology • Currently the subject of four late-stage clinical trials for pruritus • Phase 2 trial targeting pruritus in patients with CKD produced positive top

Slide 26: Leadership Team
Leadership Team Winston Black Chief Executive Officer • Appointed CEO in 2016 • Co-founded PBS Capital Management • Prior leadership positions at Highland Capital Management, Mallette Capital Management and ATX Communications Charles Jacobsen Chief Financial Officer • Appointed CFO in 2012 • Current

Slide 27: Growth Opportunity
Growth Opportunity LIFE SCIENCE SPECIALTY FINANCE ENTERIS BIOPHARMA • SWK’s underwriting process has generated portfolio yields amongst the highest in the peer group • Deal pipeline remains strong and post SRC process, anticipate originations returning to historical levels in 2022 • SWK confident in

Slide 28: Why Invest in SWKH – Attractive Risk Reward Scenario
Why Invest in SWKH – Attractive Risk Reward Scenario 28 Attractive Valuation • SWK story is not widely known, having uplisted to Nasdaq without benefit of traditional IPO • Analyst coverage and proactive investor relations effort have helped to increase SWK’s visibility Strong Management/ Proven Pro

Slide 29: Balance Sheet
Balance Sheet In 2019 and 2018 certain asset and liabilities were classified as “current”; thus prior periods may not be directly comparable. $ in 000s Sep-21 Dec-20 Dec-19 Dec-18 Dec-17 ASSETS Cash and cash equivalents $ 18,639 $ 3,008 $ 11,158 $ 20,227 $ 30,557 Interest and accounts receivable, ne

Slide 30: Income Statement
Income Statement $ in 000s, except per share amounts LTM 3Q21 Dec-20 Dec-19 Dec-18 Dec-17 Revenues Finance receivable interest income, including fees $ 37,919 $ 30,800 $ 30,117 $ 25,978 $ 26,877 Pharmaceutical development 13,673 5,903 621 - - Income related to investments in unconsolidated entities

Slide 31: Cash Flow Statement
Cash Flow Statement $ in 000s,* YTD Sept-21 Dec-20 Dec-19 Dec-18 Dec-17 Cash flows from operating activities: Consolidated net income $19,602 $5,202 $23,828 $6,195 $8,251 Adjustments to reconcile net income to net cash provided by operating activities: Income from investments in unconsolidated entit

Slide 32: Reconciliation of Non-GAAP Adjusted Net Income
Reconciliation of Non-GAAP Adjusted Net Income „H The following tables provide a reconciliation of SWK's reported (GAAP) consolidated net income to SWK's adjusted consolidated net income (Non-GAAP) for the periods denoted in the table. The table eliminates provisions for income taxes, non-cash mark-

Slide 33: Reconciliation of Non-GAAP Specialty Finance Net Income
Reconciliation of Non-GAAP Specialty Finance Net Income „H The following tables provide a reconciliation of SWK's consolidated adjusted income before provision for income taxes, listed in the table above, to the non-GAAP adjusted net income for the specialty finance business for the periods denoted

Slide 34: Contact Information
Contact Information CONFIDENTIAL SWK Senior Management Investor & Media Relations: Tiberend Strategic Advisor .. Winston Black: .. Phone: 972.687.7251 .. Email: [email protected] .. Jody Staggs: .. Phone: 972.687.7252 .. Email: [email protected] .. Office address: .. 14755 Preston Road, Ste 105 D

Slide 35: Collaborative Approach to Life Science Financing
35 Collaborative Approach to Life Science Financing
Source: SEC EDGAR · 8-K filed Nov 23, 2021
More decks from SWK Holdings Corp
Q3 2025 Earnings Presentation29 slides · Nov 7, 2025
Merger or Acquisition (October 2025)7 slides · Oct 14, 2025
Merger or Acquisition (October 2025)12 slides · Oct 10, 2025
Q2 2025 Earnings Presentation23 slides · Aug 14, 2025
Q1 2025 Earnings Presentation31 slides · May 15, 2025
Investor Presentation (March 2025)28 slides · Mar 20, 2025